<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87533">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146651</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT008</org_study_id>
    <nct_id>NCT02146651</nct_id>
  </id_info>
  <brief_title>A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of BioChaperone to insulin lispro may accelerate the onset and shorten the
      duration of action of insulin lispro due to facilitation of the absorption of the insulin
      after subcutaneous injection.

      The aim of the trial is to investigate the dose-response and the dose-exposure relationships
      of BioChaperone insulin lispro under 3 doses, to compare the pharmacokinetics and
      glucodynamic action of BioChaperone insulin lispro at 0.2U/Kg with Humalog® at 0.2 U/Kg and
      to assess safety and tolerability of BioChaperone insulin lispro and Humalog®.

      This is a double-blinded, randomised, four-period crossover phase 2 trial using automated
      12-hour euglycemic clamps in subject with type 1 diabetes mellitus.

      Each subject will be randomly allocated to a sequence of 4 treatments, i.e. with one of
      three single doses of BioChaperone insulin lispro (0.1, 0.2 and 0.4 U/Kg) or one single dose
      of Humalog® (0.2 U/Kg) on 4 separate dosing visits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glucodynamic endpoint: Area Under the Curve GIR(0-last)</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the Glucose Infusion Rate time curve from 0 hours until the end of the clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucodynamic endpoint: GIRMax</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum Glucose Infusion Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoint: AUC Lisp(0-last)</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the insulin lispro serum concentration - time curve over the clamp procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoint: Cmax(Lisp)</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum observed serum insulin lispro concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax(lisp)</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to maximum observed serum insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamic: TGIRmax</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to maximum Glucose Infusion Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tonset of action</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from t=0 until blood glucose concentration has decreased by 5mg.dL (0.3mmol.L) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: adverse events, local tolerability, vital signs variations, ECG, laboratory safety parameters.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioChaperone insulin lispro 0.2U/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioChaperone insulin lispro 0.1U/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioChaperone insulin lispro 0.4U/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humalog® 0.2U/Kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro 0.2U/Kg</intervention_name>
    <description>Single dose of 0.2U/Kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro 0.1U/Kg</intervention_name>
    <description>Single dose of 0.1U/Kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro 0.4U/Kg</intervention_name>
    <description>Single dose of 0.4U/Kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Single dose of 0.2U/Kg body weight injected subcutaneously</description>
    <arm_group_label>BioChaperone insulin lispro 0.2U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.1U/Kg</arm_group_label>
    <arm_group_label>BioChaperone insulin lispro 0.4U/Kg</arm_group_label>
    <arm_group_label>Humalog® 0.2U/Kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus for at least 12 months

          -  Treated with multiple daily insulin injections of insulin pump for at least 12 months

          -  Body Mass Index (BMI): 18.5-28.0 Kg.m²

        Exclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Receipt of any investigational product within 3 months prior first dosing

          -  Clinically significant abnormalities as judged by the investigator

          -  Any systemic treatment with drugs known to interfere with glucose metabolism

          -  History of alcoholism or drug/chemical abuse as per investigator's judgement

          -  Use of tobacco or nicotine-contained product within 1 year prior to screening

          -  Blood or plasma donation in the past month or more than 500ml within 3 months prior
             to screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselfforschung GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grit Andersen, MD</last_name>
    <phone>+49 2131 4018-0</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Institut für stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin LISPRO</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
